EyePoint Pharmaceuticals, Inc. specializes in the research and development of small molecule-based therapeutics for ophthalmic disorders. The company's core technology, Durasert E™, is a bioerodible insert that enables the sustained release of medications directly into the eye, potentially reducing the treatment burden and injection frequency for patients. Its premier pipeline asset, DURAVYU™ (vorolanib intravitreal insert), combines a selective tyrosine kinase inhibitor with this delivery system and is undergoing global Phase 3 pivotal trials. Headquartered in Watertown, Massachusetts, EyePoint operates primarily in the United States while conducting clinical trials globally. Originally founded as pSivida Corporation, the company rebranded to EyePoint in 2018 and has since transitioned its strategic focus toward advancing its proprietary late-stage clinical programs.
